Skip to content

Virus as a cancer therapy

Oncology

Oncolytics vectors

Conventional cancer treatments have limited effectiveness in many cases. Oncolytic therapy, based on the use of armed viruses directed against tumor cells, offers new perspectives in the fight against this global scourge.

In this context, our ANCHOR™ system allows the visualization of the early stages of infection down to the single cell level and the rapid quantification of viral replication. This real-time monitoring will accelerate the understanding and development of this new anti-cancer therapy and identify activator or inhibitor of your oncolytic product.

Construction of autofluorescent oncolytic vectors

Our experience in virus modification and the speed of implementation of our system can be a real asset to your product development. The real-time visualization of the virus particles allows a rapid response to many of the problems encountered in the development of oncolytic viruses. The ANCHOR technology allows the assessment of oncolytic potential without fixation, extraction or staining.

Cell line efficiency and in vivo testing

One of the main limitations of oncolytic therapies remains the permeability of cells to viruses. Many factors influence permissiveness, such as the cell type or the target organ. Also, information about the infection capacities and replication level depending on cell types can be difficult to assess. We can test a specific oncolytic product on different cell lines and test for their infection and replication capacity according to cell origin, multiplicity of infection or presence of a compound of interest. We can also propose to test the activity of oncolytic viruses on specific mouse models.

Drug discovery, oncolytic modulators

Using autofluorescent oncolytic viruses, we can measure the impact of the presence of a molecule of interest on virus infection and replication capacities. Molecules can be from different origin such as small molecules, antibodies, siRNA. This offer will help you discover the mechanistic and biological pathways behind oncolytic activities. The oncolytic activity can be modulated by activating the oncolytic potential on specific cell lines or inhibiting targeted replication.

Interaction with pre-existing treatments

The use of anti-cancer therapies is often performed in combinations for a better anti-tumor effect. We can study for you the impact of classical anti-cancer drugs combined with your oncolytic virus. The objective is to increase efficacy by detecting synergistic combination and avoid antagonism by preventing association of molecules that will impair viral infection or replication.

Pr. Pierre Cordelier
We are fortunate to collaborate with NeoVirtech on several projects. They provide unique strategies to better address complex biological questions in live cells in real-time. With their help, we were able to visualize for the first time the behavior of oncolytic virus in preclinical models of pancreatic cancer, a disease with no cure. We obtained crystal clear experimental data that could definitely accelerate the transfer of therapeutic innovation to patient with this disease. I highly recommend Franck and team, as seeing is believing !
Pr. Pierre Cordelier
CRCT Inserm
Thursday, August 31, 2017
Dr. Philippe ErbsHead
Transgene SA is a biopharmaceutical company developing for more than 30 years innovative targeted-immunotherapies to answer unmet medical needs in the oncology and infectious disease fields. We were looking for a rapid and efficient solution to investigate the behavior of our products using high-resolution quantitative microscopy. NeoVirTech’s autofluorescence technology and screening platform allowed us to precisely visualize, understand and compare the behavior of our products directly using live cell microscopy techniques. The beauty and quality of the data they can generate open a new perspective for our activities, boosting up our research and validation processes. Thank you NeoVirTech for this ongoing precious collaboration.
Dr. Philippe ErbsHead
Oncolytic Virus Department. Transgene S.A, Illkirch Graffenstaden, France
Thursday, August 31, 2017